Company intelligence / Profile preview
Zenas BioPharma
Waltham, Massachusetts, USAzenasbio.com ↗
- Ownership
- Public · ZBIO
- Employees
- ~100
- Development stage
- Other
01
Overview
Zenas BioPharma is advancing obexelimab—a bifunctional monoclonal antibody targeting CD19 and FcγRIIb—through global clinical trials for several autoimmune diseases. The INDIGO trial in IgG4-RD has completed enrollment for its pivotal Phase 3 study, with topline results expected by year-end 2025. The MoonStone trial in relapsing MS and the SunStone trial in SLE are both ongoing at the Phase 2 stage. Early data suggest that obexelimab’s mechanism may broadly suppress pathogenic B cell activity without depleting cells, potentially offering advantages over existing therapies. Additional pipeline programs include early-stage assets such as ZB002 and ZB004 targeting other autoimmune conditions.
- Therapeutic areas
- ImmunologyNeurologyEndocrinology
- Modalities
- Monoclonal antibodies (mAbs)Bifunctional antibodiesImmunology-based therapeutics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Bristol Myers Squibb — strategic license/collaboration agreement to develop/commercialize obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong & AustraliaOut-license of anti‑IGF‑1R program for Thyroid Eye Disease to Zai Lab for Greater China
04
Financials
- Market cap
- $1.7B
- Total revenue
- $10M
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Zenas BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zenas BioPharma.